Track market-moving stories before they get noisy

Meta Platforms remains a top AI growth story, now trading at only 18x forward P/E after a 14% YTD decline. I reiterate a Strong Buy rating, viewing the recent sell-off as overblown given META's consistent top and bottom-line outperformance. META's robust historical earnings, double beats, and exposure to multi-year AI, data center, and digital ad growth are undervalued by the market.

Microsoft CEO Satya Nadella compared AI's impact to the problems globalization first caused. George Chan/Getty Images AI models are hoovering up corporate knowledge, and that's leaving one big loser, says Satya Nadella.

In an article posted on X on Sunday, the Microsoft CEO warned of a future in which a handful of AI providers capture most economic value while industries lose ownership of their knowledge.

"The last thing any of us want is a world where every company across every sector is ceding value to a few models that eat everything they see," Nadella wrote. "There is no societal permission for an AI future that hollows out entire industries."

Nadella compared the AI era to globalization, warning against repeating that dynamic.

"Think about what happened in the first phase of globalization, where entire industrial economies were hollowed out by outsourcing," he wrote. "The GDP numbers looked fine on the surface, but the displacement was real and the consequences are still being felt."

Instead, he advocated for a broad AI ecosystem in which companies keep control of their learning systems, which he said would enable innovation and retain employee expertise.

Nadella's post echoed concerns other Big Tech CEOs have been raising this year.

In a February podcast, Snowflake CEO Sridhar Ramaswamy said that the biggest software companies are at risk of being reduced to mere data sources.

"The big model makers want to create a world in which all of the data for all of the enterprises is easily available to them," Ramaswamy said. "Everything else, the world, is just a dumb data pipe that feeds into that big brain."

Ramaswamy added that Snowflake needs to operate with a "fear" that people would stop using AI agents developed by software companies and instead want an all-inclusive agent that has data from Snowflake and everywhere else.

In a January LinkedIn post, Box CEO Aaron Levie said that AI models can perform high-level knowledge work across nearly every profession, from law to strategy and scientific research.

"The question that we will have to wrestle with is, in a world where everyone has access to the same expert intelligence, how does a company differentiate?" Levie wrote. He said that context would be the answer.

Read next

Shubhangi Goel You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Microsoft AI

Item 1 of 2 A Walmart sign at its booth during the China International Supply Chain Expo in Beijing, China July 16, 2025. REUTERS/Florence Lo

[1/2]A Walmart sign at its booth during the China International Supply Chain Expo in Beijing, China July 16, 2025. REUTERS/Florence Lo Purchase Licensing Rights, opens new tab

CompaniesBEIJING, June 15 (Reuters) - China's market regulator has ordered strict ​measures by Walmart supermarket chain Sam's Club ‌to eliminate food safety risks throughout its supply chain and safeguard public dietary safety, the regulator said.

The admonition ​comes amid a push to expand in ​China during which Sam's Club racked up ⁠double-digit growth in transactions last year as ​new openings boosted its tally of membership-only stores ​to 63 nationwide, its website shows.

The Reuters Inside Track newsletter is your essential guide during the World Cup. Sign up here.

The action followed a meeting with an executive of the U.S. retailer to discuss ​recently detected food safety issues, the State ​Administration for Market Regulation said in a notice on Monday, ‌without ⁠giving the date of the meeting.

Walmart's China office did not immediately respond to a request for comment.

"We will regularly report rectification progress to the ​regulatory authorities ​and proactively ⁠accept supervision," Sam's Club said in an apology, according to a state-backed ​media outlet, the Paper.

The chain has ​set ⁠up a special task force led by management to remedy matters, along with supply chain inspections, ⁠while ​offering assurances of strict compliance ​with rules and optimal product quality control, it added.

Reporting by Liz ​Lee and Beijing newsroom; Editing by Clarence Fernandez

Our Standards: The Thomson Reuters Trust Principles., opens new tab

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across life sciences and biopharma applications.

As researchers increasingly seek higher sensitivity, greater precision and improved multiplexing capabilities, dPCR is gaining adoption across a growing range of applications traditionally served by qPCR technologies. QIAGEN is expanding the QIAcuity ecosystem with new gene expression solutions, workflow automation and analysis capabilities designed to support broader adoption of digital PCR across research and biopharma applications.

"Gene expression represents one of the largest application areas in molecular biology and a significant opportunity for digital PCR," said Thierry Bernard, CEO of QIAGEN. "By expanding the QIAcuity ecosystem with new assays, enhanced multiplexing capabilities and workflow solutions, we are helping customers apply digital PCR to a broader range of research and biopharma applications."

The latest additions to the QIAcuity portfolio include:

New gene expression solutions for dPCR: QIAGEN plans to expand its portfolio later in 2026 with new QIAcuity Gene Expression Assays designed to support gene expression analysis across human, mouse and rat research applications. The company also plans to introduce the new QIAcuity OneStep High Multiplex Probe PCR Kit, enabling analysis of up to 12 RNA targets in a single reaction and helping researchers generate richer biological insights while reducing sample consumption, hands-on time and workflow complexity. These additions complement QIAGEN's GeneGlobe platform, providing access to more than 10 million predesigned assays as well as custom assay design capabilities for specialized research needs. Expanded Cell and Gene Therapy quality control portfolio: Building on its established portfolio of dPCR solutions for Cell and Gene Therapy applications, QIAGEN is expanding its residual DNA testing offering to support additional producer cell systems, including Sf9/Baculovirus, Pichia pastoris, Vero and Mouse. The portfolio also includes the recently launched QIAcuity HEK293 resDNA Sizing Kit, which enables precise measurement of both host-cell DNA concentration and fragment size distribution to support biopharmaceutical development and manufacturing workflows. Enhanced automated analysis and reporting with QIAcuity Software 3.5: Scheduled for release later this month, QIAcuity Software 3.5 introduces advanced analysis templates and automated reporting capabilities that enable users to define analysis and reporting parameters before a run begins. The software helps laboratories automate and standardize data interpretation and reporting through predefined analysis and reporting templates. By automatically applying analysis parameters and generating reports after run completion, laboratories can reduce manual review steps while improving traceability, consistency and operational efficiency, particularly in larger-scale and regulated workflows. Expanded laboratory automation through Hamilton integration: In addition to the automated analysis and reporting capabilities introduced with QIAcuity Software 3.5, customers can build on QIAGEN's collaboration with Hamilton to automate QIAcuity dPCR nanoplate setup and handling workflows, including sample preparation, nanoplate filling and sealing. Integration with robotic systems enables fully automated workflows from assay setup through data analysis, helping high-throughput laboratories increase productivity while minimizing risks associated with manual handling. QIAcuity adoption continues to grow across academia, biopharma and clinical research, with over 3,200 cumulative placements worldwide since launch. More than 400 customers now operate multiple QIAcuity instruments, while over 1,100 scientific publications reference the platform. The continued expansion of the QIAcuity ecosystem reflects QIAGEN's strategy to support customers throughout the transition from qPCR to dPCR and toward increasingly scalable, automated and standardized dPCR workflows.

Additional details on QIAGEN's QIAcuity dPCR strategy, technology roadmap and growth opportunities will be discussed during the upcoming QIAcuity Deep Dive event on Monday, June 15, 2026. The event will be webcast and available to investors, analysts and other interested stakeholders. More information is available at https://corporate.qiagen.com/English/investor-relations/events-and-presentations/QIAGEN-Deep-Dive--QIAcuity-digital-PCR/default.aspx.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Source: QIAGEN N.V.

Category: PCR & Genomics

More News From QIAGEN N.V.

Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilurgisertib, an investigational oral activin receptor-like kinase 2 (ALK2) inhibitor, in adolescents and adults (≥12 years of age) with fibrodysplasia ossificans progressiva (FOP). Results were shared in a late-breaking rapid-fire presentation at ENDO 2026, the Endocrine Society’s annual meeting.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614539468/en/

Results from Cohort 1 of the PROGRESS study demonstrated a consistent treatment effect across measures of disease activity and durability through Week 48. During the open-label extension, no new HO lesions were observed among patients who continued to receive zilurgisertib or among placebo-treated patients who crossed over to active treatment at Week 24.

"The findings presented at ENDO represent an important milestone for the zilurgisertib program and further strengthen the growing body of clinical evidence supporting its potential as a treatment for FOP," said Steven Stein, M.D., Executive Vice President, Chief Medical Officer and Head of Late-Stage Development at Incyte.

"People living with FOP and their families urgently need additional treatment options," said Joanne Quan, M.D., Chief Medical Officer at Mirum Pharmaceuticals. "These results reinforce our confidence in the potential of zilurgisertib and our commitment to working with Incyte to bring this important program forward as we prepare for potential commercialization and support the FOP community."

Cohort 1 of the PROGRESS study evaluated zilurgisertib 100 mg once-daily in 63 adolescents and adults (≥12 years of age) with FOP. Patients were randomized 1:1 to receive zilurgisertib (n=32) or placebo (n=31) during a 24-week, placebo-controlled, double-blind period, followed by an open-label extension period. Baseline demographics and disease characteristics were generally balanced between treatment groups, with a mean age of approximately 21 years and evidence of recent disease activity prior to enrollment. A total of 61 patients had 48-week whole-body CT scan data available at the time of the open-label extension analysis.

Key efficacy findings included:

Fewer patients receiving zilurgisertib developed new HO lesions at Week 24, with an 81% reduction versus placebo (p=0.0986). 99.9% reduction in total volume of new HO lesions in patients receiving zilurgisertib versus placebo at Week 24 (nominal p-value<0.0001). Reduction in total existing HO lesion volume compared with an increase observed in placebo-treated patients at Week 24 (nominal p-value=0.004). Among patients receiving zilurgisertib, no new HO lesions were observed and total HO lesion volume continued to decrease from Week 24 to Week 48. Among patients who crossed over from placebo to zilurgisertib, no new HO lesions were observed and total HO lesion volume decreased from Week 24 to Week 48. Key Efficacy Findings (Week 24 Placebo-Controlled Period and Week 48 Crossover)

Endpoint

Zilurgisertib (ZGB)

(n=32)

Week 24

Placebo

(n=31)

Week 24

Key Finding

Open-Label Extension

Week 48

Number (%) of patients who developed new HO lesions

1 (3.1)

5 (16.7)

81% reduction vs placebo

No patients with new HO lesions observed at Week 48 (n=61)

P-value

0.0986

Mean (SD) total number of new HO lesions

0.06 (0.35)

0.23 (0.63)

Fewer new lesions vs placebo

No new lesions observed (n=61)

Mean (SD) new lesion volume, cm³

0.003 (0.02)

6.57 (20.70)

99.9% reduction vs placebo

No new lesions observed (n=61)

P-value

<0.0001*

Mean (SD) change in total lesion volume, cm³

-3.24 (19.86)

24.64 (51.94)

Reduction vs increase on placebo

Continued reduction from Week 24

-6.37 (19.43) ZGB (n=32) -5.32 (20.91) crossover (n=29) P-value

0.004*

Mean (SD) new flares (annualized)

2.34 (6.06)

4.55 (7.71)

Lower flare activity vs placebo

Low flare activity maintained

1.01 (3.26) ZGB (n=32) 1.22 (2.54) crossover (n=30) *Nominal P-value

Zilurgisertib was generally well-tolerated during the 24-week placebo-controlled period of the study. Data showed:

Most adverse events were mild or moderate in severity. No adverse events led to treatment discontinuation or dose reduction. Serious adverse events and Grade ≥3 adverse events occurred at low rates in both treatment groups. The most commonly reported adverse events among patients receiving zilurgisertib were FOP flare-up or aching/pain due to FOP (25%), headache (21.9%), upper respiratory tract infection (21.9%), arthralgia (18.8%), epistaxis (12.5%), and nausea (12.5%). The full abstract is available on the Endocrine Society’s ENDO 2026 website. Detailed analyses are also posted on the Publications & Presentations section of Mirum’s website.

The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for zilurgisertib for the treatment of FOP in patients 12 years of age and older and granted Priority Review. The Prescription Drug User Fee Act (PDUFA) target action date for zilurgisertib is September 26, 2026.

About Zilurgisertib

Zilurgisertib is an investigational, oral, small molecule, activin receptor-like kinase 2 (ALK2) inhibitor in development for the treatment of Fibrodysplasia Ossificans Progressiva (FOP). Zilurgisertib is designed to inhibit the ALK2 receptor, which is abnormally active in most patients with FOP and leads to bone formation in soft tissues, a process known as heterotopic ossification (HO). FOP is an ultra-rare genetic disease that affects approximately 300 patients in the U.S. and 900 worldwide, with diagnosis typically occurring in early childhood. Zilurgisertib was evaluated in the PROGRESS pivotal Phase 2 study, which formed the basis of a new drug application (NDA). The FDA has accepted the NDA for zilurgisertib in FOP under Priority Review with a Prescription Drug User Fee Act (PDUFA) date of September 26, 2026.

Mirum Pharmaceuticals, Inc. licensed zilurgisertib from Incyte for worldwide development and commercialization.

About the PROGRESS Study

PROGRESS is a global, randomized, double-blind, placebo-controlled Phase 2 study evaluating the efficacy and safety of zilurgisertib in patients with fibrodysplasia ossificans progressiva (FOP). PROGRESS Cohort 1 enrolled patients 12 years of age and older who were randomized 1:1 to receive zilurgisertib 100 mg once daily or placebo during a 24-week double-blind treatment period, followed by an open-label extension. Additional PROGRESS cohorts will evaluate the efficacy and safety of zilurgisertib in patients ages 6 to <12 years of age (Cohort 2) and in patients ages 2 to <12 years of age (Cohort 3).

The primary endpoint of the study is the proportion of Cohort 1 patients with new heterotopic ossification (HO) lesions at Week 24 as assessed by whole-body CT scan data. Key secondary endpoints include the number and total volume of new HO lesions, changes in total HO lesion volume and flare activity through Week 24.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX).

Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), zilurgisertib, an ALK2 inhibitor under regulatory review with the FDA for fibrodysplasia ossificans progressiva (FOP), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).

Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at www.mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and X.

About Incyte®

Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation & Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.

Mirum Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the Company’s planned participation at a scientific congress, Mirum’s continued advancement of zilurgisertib with Incyte, the likelihood of a FDA approval pathway for zilurgisertib and the potential benefit of zilurgisertib in real world settings versus scientific presentations of data. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “expected,” “will,” “could,” “would,” “guidance,” “potential,” “continue” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Mirum’s business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Mirum’s Annual Report for the year ended December 31, 2025, filed with the Securities and Exchange Commission on February 25, 2026, and subsequent filings with the Securities and Exchange Commission, which are available at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Incyte Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the presentation of data from the PROGRESS study; the potential for zilurgisertib to become a treatment option for people living with FOP; expectations regarding ongoing and future clinical trials for zilurgisertib, including the timing of such trials; and Incyte’s aspirations and goals as set forth under the heading “About Incyte.”

Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including the sufficiency of clinical trial data to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; the efficacy or safety of Incyte’s and its partners’ products; the ability of Incyte and its partners to achieve commercial success for their marketed products and product candidates, if approved; Incyte’s and its partners’ ability to obtain and maintain protection of intellectual property for their products and technology; Incyte’s reliance on third parties and partners; the acceptance of Incyte’s and its partners’ products in the marketplace; market competition, sales, marketing, manufacturing and distribution requirements; greater than expected expenses, including expenses relating to litigation or strategic activities; and those risks and uncertainties discussed in greater detail in Incyte’s reports filed with the U.S. Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2025, and its quarterly report on Form 10-Q for the quarter ended March 31, 2026. Incyte disclaims any intent or obligation to update these forward-looking statements.

Mirum and the Mirum logo are trademarks of Mirum Pharmaceuticals, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260614539468/en/

ComEd crews have nearly completed the restoration of power to customers impacted by multiple rounds of severe storms that moved through northern Illinois beginning Wednesday afternoon. With 99% of affected customers now restored, crews are in the final stages of repairs and remain committed to completing service restoration for all remaining customers.

Multiple bands of severe weather moved through ComEd's northern Illinois service territory on Wednesday and Thursday, bringing intense rain, frequent lightning, and high wind gusts — with speeds reaching roughly 80 mph at peak — causing significant damage to ComEd's infrastructure and resulting in widespread outages across the service territory. At least two tornadoes were confirmed on Thursday, including one in Streator, Illinois, approximately 100 miles southwest of Chicago, and another near Dwight, Illinois, about 80 miles southwest of Chicago, with additional damage assessments ongoing.

Large trees fell across equipment and blocked access to neighborhoods with restoration needs, and hundreds of utility poles were broken and had to be completely replaced. That type of work is complex and takes more time to do safely, even with crews working around the clock. In total, crews replaced nearly 500 poles and used more than 295,000 feet of cable wire during the restoration effort.

Across the two days of severe weather, more than 674,600 ComEd customers experienced outages. Late Saturday evening, isolated thunderstorms produced localized strong wind gusts that caused additional tree and limb damage, resulting in an additional 6,425 outages.

"Our crews have worked tirelessly — around the clock and under challenging conditions — to safely restore power to our customers, and their dedication throughout this storm event has been extraordinary," said David Perez, executive vice president and COO of ComEd. "We are incredibly grateful for their hard work and commitment over the duration of this event. We also want to sincerely thank our customers for their patience and understanding as we worked through the most significant storm damage our service territory has experienced since the 2020 Derecho. We will not rest until the final customers are restored."

More than 3,000 ComEd employees and 2,200 contractors were mobilized during the peak of the response, supported by roughly 400 mutual assistance personnel who arrived Friday to bolster ComEd staff and contractors in their restoration efforts.

Public Safety Reminders

Public safety remains paramount, and ComEd encourages customers to take the following precautions:

If a downed power line is spotted, please immediately call ComEd at 1-800-EDISON1 (1-800-334-7661). Spanish-speaking customers should call 1-800-95-LUCES (1-800-955-8237). Never approach a downed power line. Always assume a power line is energized and extremely dangerous. In the event of an outage, do not approach ComEd crews working to restore power to ask about restoration times. Crews may be working on live electrical equipment, and the perimeter of the work zone may be hazardous. ComEd urges customers to contact the company immediately if they experience a power outage. Customers can text OUT to 26633 (COMED) to report an outage and receive restoration information and can follow the company on X @ComEd or on Facebook at Facebook.com/ComEd. Customers can also call 1-800-EDISON1 (1-800-334-7661), or report outages via the website at ComEd.com/report. Spanish-speaking customers should call 1-800-95-LUCES (1-800-955-8237).

With ComEd’s Outage Tracker, customers can report outages, check estimated time of restoration, view crew status updates, and explore our outage map. Visit ComEd.com/OutageTracker.

ComEd’s mobile app for iPhone and Android® smart phones gives customers the ability to report power outages and manage their accounts; download the app at ComEd.com/app.

ComEd is a unit of Chicago-based Exelon Corporation (NASDAQ: EXC), a Fortune 200 company and one of the nation’s largest utility companies, serving nearly 11 million electricity and natural gas customers. ComEd powers the lives of more than 4 million customers across northern Illinois, or 70 percent of the state’s population. For more information, visit ComEd.com, and connect with the company on Facebook, Instagram, LinkedIn, X and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260614495118/en/

AV Introduces TOM 50 RE, a Backpackable UGV for Rapid Reconnaissance and Explosive Ordnance Disposal AeroVironment, Inc. (“AV”), a global leader in autonomous systems, today announced the launch of TOM 50 RE, a compact, backpackable uncrewed ground vehicle (UGV) developed by its wholly owned subsidiary Telerob.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615133056/en/

AV’s TOM 50 RE backpackable UGV delivers rapid reconnaissance, explosive ordnance disposal, and autonomous mapping capabilities for dismounted forces operating in contested environments. (Photo: AV)

Designed for mobile exploration, mission-accompanying reconnaissance, explosive threat disposal, and operational support, TOM 50 RE enables dismounted forces, explosive ordnance disposal (EOD) teams, and special operations units—including SWAT—to rapidly deploy robotic capability wherever the mission demands.

The announcement was made at Eurosatory 2026, a global event for defence and security held in Paris.

“The introduction of TOM 50 RE reflects AV’s commitment to delivering robotic systems that directly address the realities of modern ground combat and explosive threat environments,” said Wahid Nawabi, Chairman, President, and Chief Executive Officer of AV. “Today’s operators need systems that move with them, adapt to multiple missions, and provide immediate intelligence while reducing risk to human life. TOM 50 RE delivers that capability in a highly portable form factor built for the tactical edge.”

Weighing less than 10 kilograms (22 pounds) and compact enough to be carried by a single operator, TOM 50 RE enables rapid deployment in confined and complex terrain, while its tracked design, stair-climbing flipper system, and dedicated mobility attachments allow it to overcome obstacles, navigate stairs and uneven terrain, and operate inside structures, delivering up to five hours of endurance and supporting payloads of up to five kilograms without compromising mobility.

With state-of-the-art onboard simultaneous localization and mapping (SLAM) capability, TOM 50 RE autonomously generates detailed maps of interior spaces, including multi-level buildings and global positioning system (GPS)-denied environments such as underground structures and dense urban terrain. Operators can identify and record points of interest directly within the digital map and export mission data immediately following operations, accelerating intelligence exploitation, supporting informed decision-making, and enabling more effective follow-on planning.

Equipped with four integrated high-resolution wide-angle cameras with infrared capability, TOM 50 RE delivers persistent 360-degree situational awareness in day, night, and degraded visual environments. Its advanced internet protocol (IP)-mesh radio architecture provides secure, resilient communications while enabling the system to function as a mobile repeater, extending connectivity for forces operating deep inside structures or complex terrain.

Its modular architecture, enabled by the Mission Module Interface (MMI) or an adapter supporting Telerob’s Universal Component Interface (UCI), allows operators to integrate mission-specific payloads, including advanced camera systems and disruptors, and tailor the system to evolving operational requirements.

“TOM 50 RE was designed to deliver immediate robotic capability at the point of need, where operators face the greatest uncertainty and risk,” said Florian Gruener, Managing Director of Telerob and Product Line General Manager for Uncrewed Ground Vehicles. “Its ability to rapidly conduct these missions in complex terrain allows forces to gain critical situational awareness, mitigate threats, and make faster, more informed decisions—while keeping personnel out of harm’s way.”

Controlled through AV_Halo™ Command running on the Tomahawk Grip family of systems or the Robo Command Control System, operators can seamlessly manage TOM 50 RE alongside other uncrewed systems, enabling coordinated robotic operations and enhancing situational awareness across the mission.

The Four Missions

For mobile exploration, TOM 50 RE provides immediate situational awareness in unknown or high-risk environments, allowing operators to scout structures, confined spaces, and urban terrain without exposing personnel to danger. In mission-accompanying reconnaissance, the system’s integrated simultaneous localization and mapping (SLAM) capability enables it to navigate multi-story buildings, generate detailed interior maps, and identify and mark hazards or points of interest for follow-on forces. In defusing missions, TOM 50 RE supports the safe neutralization of improvised explosive devices and explosive hazards through modular disruptor and drop-charge payloads, allowing operators to mitigate threats from a safe distance. In its support role, in cooperation with the telemax EVO family of products, the system can serve as a mobile communications relay, extend operational reach, provide additional viewing angles, and enhance coordination between robotic and human elements across distributed teams. TOM 50 RE expands AV’s portfolio of intelligent, mission-ready ground robotic systems supporting defence, security, and public safety forces worldwide.

About AV

AV (NASDAQ: AVAV) is a defence technology leader delivering integrated capabilities across air, land, sea, space, and cyber. The Company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities—built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo™, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. For more information, visit www.avinc.com.

Safe Harbor Statement

Certain statements in this press release may constitute "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, and assumptions that involve risks and uncertainties, which could cause actual results to differ materially. Factors that may cause such differences include, but are not limited to, our ability to perform under existing contracts and obtain new ones; regulatory changes; competitor activities; market growth; product development challenges; and general economic conditions. For a more detailed discussion of these risks, please refer to AeroVironment’s filings with the Securities and Exchange Commission. We undertake no obligation to update forward-looking statements as a result of new information or future events.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260615133056/en/

HomeStock IdeasLong IdeasFinancials 

SummaryOWL is deeply undervalued after a 58% crash.The market is afraid of AI disruption and worse inflows.But OWL's portfolio has expanded from 3 to 8 segments in 4 years, with digital infrastructure now 6% of AUM and strong inflows continuing.I believe OWL will be one of the AI's beneficiaries, not its victim.I think OWL is undervalued, and its business stance is much stronger than it seems. That's why I consider it a once-in-a-decade opportunity. peshkov/iStock via Getty Images

Since I published my latest article about Blackstone (BX), I kept Blue Owl Capital (OWL) on my radar. Because I see a great opportunity in the whole sector. And I suspect that OWL

5.09K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of BX, OWL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The information, opinions, and thoughts included in this article do not constitute an investment recommendation or any form of investment advice.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

On June 12, SpaceX (SPCX +19.17%) completed the largest initial public offering (IPO) in history, raising about $75 billion at a valuation of about $1.75 trillion -- more than double the size of any stock market debut before it. By the closing bell, the stock had jumped 19%, lifting the rocket-and-satellite company's value above $2 trillion.

SpaceX went public in the middle of a wave of artificial intelligence (AI) spending unlike anything the market has seen, with the four biggest technology companies alone on track to pour about $725 billion into capital expenditures (much of it on data centers and chips this year) -- up about 77% from last year. To some investors, a record listing landing on top of all that spending looks like the kind of enthusiasm that shows up near market tops. To others, it's a rational response to seemingly insatiable demand that remains largely unmet.

So, is this the top? Here's a look at both arguments.

Image source: Getty Images.

The bear case Bursts of giant, money-losing IPOs have often clustered near market peaks, and SpaceX fits the profile. The company priced at more than 90 times its 2025 revenue while posting a $4.9 billion net loss for the year -- a loss driven largely by the AI unit, the former xAI, that Elon Musk folded into the company.

Yet demand for the IPO was heavy enough that the offering was oversubscribed several times over, with retail investors alone reportedly submitting more than $70 billion in orders.

The backdrop looks stretched, too.

The S&P 500's cyclically adjusted price-to-earnings ratio sits near 40 -- a level it has touched only once before, during the dot-com bubble.

Then there's the spending. The four biggest AI spenders -- Amazon (AMZN 1.24%), Microsoft, Alphabet (GOOG +0.44%)(GOOGL +0.53%), and Meta Platforms -- are spending so heavily that their free cash flow has plummeted. Indeed, Amazon's trailing free cash flow has fallen about 95%, to $1.2 billion, and its 2026 capital expenditures of about $200 billion look poised to outrun its operating cash flow, turning free cash flow negative for the year. To keep building, the group has leaned heavily on the bond market, and Alphabet recently announced a massive $85 billion equity raise.

Meanwhile, the payoff remains hard to find. A widely cited MIT study found that about 95% of corporate generative-AI pilots have yet to produce a measurable return, and in PwC's latest global survey, 56% of CEOs said they were getting essentially nothing from their AI efforts so far.

The bull case But the other side of the argument starts with a simple observation -- the demand is extraordinary.

"[W]e are compute constrained in the near term," said Alphabet CEO Sundar Pichai during the company's first-quarter 2026 earnings call. "... [O]ur cloud revenue would have been higher if we were able to meet the demand."

In other words, Alphabet is turning away cloud revenue because it can't add capacity fast enough. Behind that comment, Google Cloud revenue grew 63% in the first quarter, and its backlog (contracted business it hasn't yet delivered) nearly doubled sequentially to more than $460 billion. The other big providers are growing quickly as well, with Amazon's AWS accelerating sequentially to a year-over-year growth rate of 28%.

Today's Change

(

0.53

%) $

1.90

Current Price

$

359.67

The bulls also point out that these companies have done this before. The same cloud and data center investments that critics once called reckless have become highly profitable businesses. From that view, spending ahead of demand is how the last technology cycle was won, not a warning sign -- and Goldman Sachs projects AI-related spending will climb toward $1.6 trillion a year by 2031.

So, where does this leave investors?

Both sides of the argument deserve some consideration. The skeptics are right that valuations are rich and that we're still largely waiting to see profits big enough to justify this unprecedented spending cycle. And the optimists are right about demand: backlogs are massive, and they seem to keep climbing.

To me, the honest read is that neither camp has won the argument yet. Which one turns out to be right will come down to the single question neither can answer today -- whether all of that spending eventually produces the profits to justify it.

With all of this said, I believe investors may want to consider allocating some of their portfolio to areas that could benefit if the AI boom continues longer than expected, as well as to more conservatively valued investments, with exposure to sectors likely to be more resilient during a pullback in AI spending.

As excitement builds around a potential SpaceX (SPCX +19.17%) investment, many Alphabet (GOOG +0.44%)(GOOGL +0.53%) shareholders already hold indirect exposure through its stake. Discover why leverage, volatility, and a long‑term mindset matter so much by watching the discussion in the video below.

*This video was published on Jun. 12, 2026.

Lou Whiteman has no position in any of the stocks mentioned. Sanmeet Deo, CFA has positions in Alphabet. Tim Beyers has positions in Alphabet. The Motley Fool has positions in and recommends Alphabet. The Motley Fool has a disclosure policy.

HomeStock IdeasQuick Picks & Lists

SummaryThe Undercovered Dozen series spotlights 12 lesser-covered stocks featured on Seeking Alpha between June 5 and June 11.This curated selection aims to provide fresh investment ideas and foster community discussion around under-the-radar equities.Readers are encouraged to engage, share perspectives, and highlight additional overlooked investment opportunities.The series serves as a catalyst for discovering unique stocks that may warrant further research and portfolio consideration. brlozier/iStock via Getty Images

The Undercovered Dozen is a weekly Seeking Alpha editor-curated series highlighting 12 articles on lesser-covered stocks from the previous seven days. We hope this provides ideas and inspires discussion among the community.

Today, we're looking at

2.83K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given that any particular security, portfolio, transaction or investment strategy is suitable for any specific person. The author is not advising you personally concerning the nature, potential, value or suitability of any particular security or other matter. You alone are solely responsible for determining whether any investment, security or strategy, or any product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. The author is an employee of Seeking Alpha. Any views or opinions expressed herein may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

Hasbro remains a buy as Wizards of the Coast drives recurring, high-margin growth and Magic's momentum proves more durable. Magic's ecosystem expansion, record-setting sales, and robust backlist/Secret Lair growth support a shift from hit-driven to recurring revenue. HAS management's FY2026 guidance appears conservative, leaving room for beat-and-raise upside if Magic demand and Consumer Products rebound.

Lexington, NC , June 14, 2026 (GLOBE NEWSWIRE) -- Sky Aircraft Maintenance (SAM), an FAA-certified Part 145 Repair Station and member of the Atlantic Jet Partners family of companies, is proud to announce that it has been named an authorized Garmin Aviation dealer.

The new dealership allows Sky Aircraft Maintenance to provide factory-authorized Garmin avionics sales, installation, integration, and support for private and business aircraft owners and operators seeking modern flight deck solutions.

Sky Aircraft Maintenance

Garmin has become one of the most trusted names in aviation avionics, offering advanced navigation systems, flight displays, digital autopilots, ADS-B solutions, connected aircraft technologies, and integrated flight deck modernization programs. As an authorized Garmin dealer, Sky Aircraft Maintenance can now support a wide range of Garmin upgrades, from focused avionics improvements to complete cockpit transformations.

One of the most significant opportunities for business aircraft operators is Garmin's G5000 integrated flight deck retrofit program. Available for select aircraft including the Beechjet 400A, Hawker 400XP, and Citation 560XL / Excel / XLS series, the G5000 replaces aging avionics architecture with a modern integrated flight deck featuring touchscreen controllers, advanced navigation capability, digital autopilot integration, wireless cockpit technology, and enhanced situational awareness.

For many operators, a G5000 retrofit provides a practical path to extend the useful life of proven airframes while addressing avionics obsolescence, improving reliability, and enhancing long-term supportability.

In addition to flight deck modernization, Garmin's wireless cockpit technologies help streamline pilot workflow through wireless flight plan transfer, avionics database management, mobile device integration, and connected aircraft capabilities that simplify cockpit operations before, during, and after flight.

"Aircraft owners and operators are looking for solutions that improve capability, reduce pilot workload, and help protect the long-term value of their aircraft," said Christopher Arnett of Sky Aircraft Maintenance. "Garmin continues to lead the industry with products that accomplish those goals, and we're excited to bring those solutions to our customers as an authorized Garmin dealer."

Sky Aircraft Maintenance can now assist customers with:

• Garmin G5000 integrated flight deck retrofits
• GTN Xi navigator installations
• TXi flight display upgrades
• GI 275 electronic flight instrument retrofits
• Garmin digital autopilot installations
• ADS-B compliance solutions
• Wireless cockpit and connected aircraft technologies
• Complete avionics modernization projects

As a full-service maintenance facility, Sky Aircraft Maintenance can also coordinate Garmin avionics upgrades alongside scheduled inspections, maintenance events, connectivity upgrades, interior refurbishments, and other aircraft services. This approach helps reduce downtime and allows owners to accomplish multiple projects during a single visit.

To celebrate the new Garmin dealership, aircraft owners and operators are encouraged to contact Sky Aircraft Maintenance to learn more about current avionics upgrade opportunities and how they may qualify for 10% off scheduled maintenance when combined with a Garmin avionics upgrade.

To learn more about Garmin avionics solutions available through Sky Aircraft Maintenance, visit: https://atlanticjetpartners.com/garmin-avionics-aircraft-upgrades/

About Sky Aircraft Maintenance 

Sky Aircraft Maintenance is an FAA-certified Part 145 Repair Station located in Lexington, North Carolina. SAM provides aircraft maintenance, avionics installation, inspections, connectivity upgrades, interior refurbishments, pre-purchase inspections, and aircraft modernization services for private and business aircraft operators throughout North America.

For additional information, contact:

Sky Aircraft Maintenance
843-729-1177
https://atlanticjetpartners.com

Sky Aircraft Maintenance Named Authorized Garmin Aviation Dealer

Sky Aircraft Maintenance Named Authorized Garmin Aviation Dealer New Garmin dealership expands avionics modernization capabilities for private and business aircraft ...

Dell Stock Surge Boosts Michael Dell's Net Worth By $72 BillionThe ongoing Dell stock surge has pushed its market capitalization to over $256 billion. This surge has helped to push Michael Dell's net worth by $72 billion this year to $213 billion, making him the 6th wealthiest person in the world.

Michael owns about 40% of Dell Technologies. At the same time, he owns DFO Management, an asset management company that manages his wealth and invests in hotels and liquid corporate credit. 

Dell shares have jumped this year as the company became a major player in the AI infrastructure industry. That is because it sells items like servers and networking equipment that are used by the biggest hyperscalers. 

A report released in May showed that the company was firing on all cylinders. Its revenue jumped by 88% in the first quarter to $43.8 billion. This growth was driven by its infrastructure division, whose revenue soared by 181% to $29 billion. Its servers soared by 757% to $16.1 billion. 

Dell's client solutions group made over $14.6 billion in Q1, up by 17% from the same period last year. As a result, the company boosted its forward guidance and continued to return funds to its shareholders. It now expects that its revenue will jump by 50% in Q2 to $45 billion, while its full-year figure will soar by 47% to $169 billion.

Dell stock is also benefiting from a recently-announced $9.7 billion deal with the Department of War. This deal also includes Microsoft (NASDAQ:MSFT) services and is expected to save the government over $422 million. 

Dell Valuation Multiples Point to More GainsThe ongoing Dell stock surge may have more room to run based on momentum and the fact that the company is not all that expensive. Data shows that the company has a forward price-to-earnings ratio of 22, slightly lower than the S&P 500 Index average of 23. This is crucial as the company is growing at a faster pace than the broader stock market by far.

Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

A view shows Woodside Energy's headquarters in Perth, Australia, April 19, 2025. REUTERS/Christine Chen/File Photo Purchase Licensing Rights, opens new tab

CompaniesJune 15 (Reuters) - Australia's Woodside Energy (WDS.AX), opens new tab ​said on Monday it was ‌not aware of any proposal involving U.S. energy major Exxon Mobil (XOM.N), opens new tab ​and was not engaged in ​discussions regarding a potential transaction, ⁠responding to recent media speculation.

The ​statement follows media reports that Exxon ​is studying a potential acquisition of the LNG producer as part of efforts ​to deepen its presence ​in liquefied natural gas and Asian markets.

The Reuters Power Up newsletter provides everything you need to know about the global energy industry. Sign up here.

Western ‌Australia ⁠Premier Roger Cook said on Sunday the government would oppose any takeover that involved relocating Woodside's ​headquarters from ​the ⁠state, where it has been based since the ​1990s.

Woodside is Australia's leading LNG ​exporter ⁠and recently increased its stake in the Browse project to about ⁠42%, ​reinforcing its role ​in future supply growth.

Reporting by Roshan Thomas ​in Bengaluru; Editing by Tom Hogue

Our Standards: The Thomson Reuters Trust Principles., opens new tab

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Building $3,000 a month in dividend income before age 50 can transform the way you think about work. While it may not fully replace a salary, it can cover a mortgage payment, health insurance, or a large share of household expenses, creating the freedom to reduce hours, change careers, take a sabbatical, or pursue work on your own terms. Reaching that milestone is less about finding a magical stock and more about accumulating enough capital to generate a reliable income stream.

The math is straightforward. Generating $36,000 per year in dividend income requires a portfolio large enough to support that cash flow. Divide the income target by the portfolio yield, and you have the capital required. The amount varies dramatically depending on the yield you target, which is why there are three very different paths to reaching $3,000 a month in dividend income before age 50.

The Conservative Path: Dividend Growth at 3% to 4% At a 3.5% blended yield, you need roughly $1,028,571 invested. At 4%, the number drops to $900,000. This is the lane built around dividend aristocrats and broad dividend-growth funds.

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is the archetype. The board just lifted the quarterly payout to $1.34, extending 64 consecutive years of dividend growth, even though the current yield is only about 2.3%. Procter & Gamble (NYSE:PG) yields roughly 3% and has now strung together 70 straight annual increases. Coca-Cola just bumped its quarterly dividend to $0.53, a 2.7% yield.

For a one-fund version, the Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) holds $71.6 billion in assets at a 0.06% expense ratio. The tradeoff in this tier is straightforward: you need the most capital, but the income stream grows, and the principal tends to compound alongside it.

The Moderate Path: REITs and High-Yield Equity at 5% to 7% At a 6% yield, the required capital drops to $600,000. At 7%, it falls to roughly $514,000. This tier leans on net-lease REITs, preferred shares, covered-call equity funds, and high-yield consumer names.

Realty Income (NYSE:O) pays monthly, currently $0.2705 per share, an annualized $3.246 that works out to about a 5.4% yield. Altria yields close to 6% on a $4.24 annualized payout, with management guiding to mid-single-digit EPS growth.

You give something up here: dividend growth typically slows, some structures cap upside, and the income stream is more vulnerable to inflation eroding its real value over a long horizon. With the core PCE index continuing to climb, that risk is not abstract.

The Aggressive Path: 8% to 12% Yields At 10%, you only need $360,000 to clear $3,000 a month. The instruments that get you there are covered-call ETFs on the S&P 500 or Nasdaq, business development companies, mortgage REITs, and high-yield bond funds. The math is seductive. The catch is that distributions in this tier are often partially funded by return of capital, principal erodes during drawdowns, and payouts get cut when credit cycles turn. You are buying current income at the cost of long-term growth.

For context, the 10-year Treasury yields about 4.5%, so any double-digit payout carries materially more risk than the risk-free rate suggests.

The Growth Advantage Many investors focus on starting yield and overlook the power of dividend growth. A portfolio yielding 3.5% today may appear less attractive than one yielding 10%, but the gap can narrow dramatically over time if the underlying companies consistently raise their payouts. At an 8% annual growth rate, dividend income can roughly double in nine years. A high-yield portfolio with little or no growth may generate more income today, but it often struggles to increase that income meaningfully over time.

Some of the most successful dividend investments have followed this pattern. Companies such as Coca-Cola and Procter & Gamble have spent decades raising their distributions, allowing income streams to grow far faster than inflation. A $1 million portfolio yielding 3.5% today produces about $35,000 annually, but continued dividend growth could lift that income to roughly $70,000 within a decade without requiring additional contributions. By comparison, a portfolio built around a static 10% yield may provide more income upfront but offer far less growth potential.

Reaching the first $3,000 per month is often the most difficult milestone. Once dividend growth begins compounding, however, the path to $5,000 or even $7,500 per month can become much shorter than many investors expect.

Three Things to Do This Month Audit your actual essential expenses, not your salary. If your mortgage, insurance, and utilities total $2,800, your real replacement target is much lower than $36,000. Compare a 10-year total return chart of a dividend-growth fund against a high-yield covered-call fund. SCHD has returned 229% over the past decade, illustrating what compounding growth, not just yield, produces. Reinvest every dividend until the moment you actually need the income. Households are saving less, with the personal savings rate at 3.7%, so automatic reinvestment is the easiest way to keep the compounding intact. The path to $3,000 a month is plain arithmetic, and the math is honest. Pick a tier, run your number, and start.

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of Class A or Class C common stock of Zillow Group, Inc. (NASDAQ: ZG) (NASDAQ: Z) between February 11, 2025 and May 7, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 10, 2026 in the securities class action first filed by the Firm.

SO WHAT: If you purchased Zillow common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Zillow class action, go to https://rosenlegal.com/cases/zillow-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 10, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Zillow's agreement with Redfin Corporation was not a "partnership," but rather an acquisition of Redfin's business; (2) as a result of the Redfin Agreement, Zillow faced a materially heightened risk of regulatory scrutiny and liability under federal antitrust laws; (3) upon the filing of an antitrust lawsuit, Zillow continued to downplay its legal exposure; and (4) as a result, defendants' statements about Zillow's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Zillow class action, go to https://rosenlegal.com/cases/zillow-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilurgisertib, an investigational oral activin receptor-like kinase 2 (ALK2) inhibitor, in adolescents and adults (≥12 years of age) with fibrodysplasia ossificans progressiva (FOP). Results were shared in a late-breaking rapid-fire presentation at ENDO 2026, the Endocrine Society’s annual meeting.

Results from Cohort 1 of the PROGRESS study demonstrated a consistent treatment effect across measures of disease activity and durability through Week 48. During the open-label extension, no new HO lesions were observed among patients who continued to receive zilurgisertib or among placebo-treated patients who crossed over to active treatment at Week 24.

"The findings presented at ENDO represent an important milestone for the zilurgisertib program and further strengthen the growing body of clinical evidence supporting its potential as a treatment for FOP," said Steven Stein, M.D., Executive Vice President, Chief Medical Officer and Head of Late-Stage Development at Incyte.

"People living with FOP and their families urgently need additional treatment options," said Joanne Quan, M.D., Chief Medical Officer at Mirum Pharmaceuticals. "These results reinforce our confidence in the potential of zilurgisertib and our commitment to working with Incyte to bring this important program forward as we prepare for potential commercialization and support the FOP community."

Cohort 1 of the PROGRESS study evaluated zilurgisertib 100 mg once-daily in 63 adolescents and adults (≥12 years of age) with FOP. Patients were randomized 1:1 to receive zilurgisertib (n=32) or placebo (n=31) during a 24-week, placebo-controlled, double-blind period, followed by an open-label extension period. Baseline demographics and disease characteristics were generally balanced between treatment groups, with a mean age of approximately 21 years and evidence of recent disease activity prior to enrollment. A total of 61 patients had 48-week whole-body CT scan data available at the time of the open-label extension analysis.

Key efficacy findings included:

Fewer patients receiving zilurgisertib developed new HO lesions at Week 24, with an 81% reduction versus placebo (p=0.0986). 99.9% reduction in total volume of new HO lesions in patients receiving zilurgisertib versus placebo at Week 24 (nominal p-value<0.0001). Reduction in total existing HO lesion volume compared with an increase observed in placebo-treated patients at Week 24 (nominal p-value=0.004). Among patients receiving zilurgisertib, no new HO lesions were observed and total HO lesion volume continued to decrease from Week 24 to Week 48. Among patients who crossed over from placebo to zilurgisertib, no new HO lesions were observed and total HO lesion volume decreased from Week 24 to Week 48. Key Efficacy Findings (Week 24 Placebo-Controlled Period and Week 48 Crossover)

Endpoint

Zilurgisertib (ZGB)

(n=32)

Week 24

Placebo

(n=31)

Week 24

Key Finding

Open-Label Extension

Week 48

Number (%) of patients who developed new HO lesions

1 (3.1)

5 (16.7)

81% reduction vs placebo

No patients with new HO lesions observed at Week 48 (n=61)

P-value

0.0986

Mean (SD) total number of new HO lesions

0.06 (0.35)

0.23 (0.63)

Fewer new lesions vs placebo

No new lesions observed (n=61)

Mean (SD) new lesion volume, cm³

0.003 (0.02)

6.57 (20.70)

99.9% reduction vs placebo

No new lesions observed (n=61)

P-value

<0.0001*

Mean (SD) change in total lesion volume, cm³

-3.24 (19.86)

24.64 (51.94)

Reduction vs increase on placebo

Continued reduction from Week 24

-6.37 (19.43) ZGB (n=32) -5.32 (20.91) crossover (n=29) P-value

0.004*

Mean (SD) new flares (annualized)

2.34 (6.06)

4.55 (7.71)

Lower flare activity vs placebo

Low flare activity maintained

1.01 (3.26) ZGB (n=32) 1.22 (2.54) crossover (n=30) *Nominal P-value

Zilurgisertib was generally well-tolerated during the 24-week placebo-controlled period of the study. Data showed:

Most adverse events were mild or moderate in severity. No adverse events led to treatment discontinuation or dose reduction. Serious adverse events and Grade ≥3 adverse events occurred at low rates in both treatment groups. The most commonly reported adverse events among patients receiving zilurgisertib were FOP flare-up or aching/pain due to FOP (25%), headache (21.9%), upper respiratory tract infection (21.9%), arthralgia (18.8%), epistaxis (12.5%), and nausea (12.5%). The full abstract is available on the Endocrine Society’s ENDO 2026 website. Detailed analyses are also posted on the Publications & Presentations section of Mirum’s website.

The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for zilurgisertib for the treatment of FOP in patients 12 years of age and older and granted Priority Review. The Prescription Drug User Fee Act (PDUFA) target action date for zilurgisertib is September 26, 2026.

About Zilurgisertib

Zilurgisertib is an investigational, oral, small molecule, activin receptor-like kinase 2 (ALK2) inhibitor in development for the treatment of Fibrodysplasia Ossificans Progressiva (FOP). Zilurgisertib is designed to inhibit the ALK2 receptor, which is abnormally active in most patients with FOP and leads to bone formation in soft tissues, a process known as heterotopic ossification (HO). FOP is an ultra-rare genetic disease that affects approximately 300 patients in the U.S. and 900 worldwide, with diagnosis typically occurring in early childhood. Zilurgisertib was evaluated in the PROGRESS pivotal Phase 2 study, which formed the basis of a new drug application (NDA). The FDA has accepted the NDA for zilurgisertib in FOP under Priority Review with a Prescription Drug User Fee Act (PDUFA) date of September 26, 2026.

Mirum Pharmaceuticals, Inc. licensed zilurgisertib from Incyte for worldwide development and commercialization.

About the PROGRESS Study

PROGRESS is a global, randomized, double-blind, placebo-controlled Phase 2 study evaluating the efficacy and safety of zilurgisertib in patients with fibrodysplasia ossificans progressiva (FOP). PROGRESS Cohort 1 enrolled patients 12 years of age and older who were randomized 1:1 to receive zilurgisertib 100 mg once daily or placebo during a 24-week double-blind treatment period, followed by an open-label extension. Additional PROGRESS cohorts will evaluate the efficacy and safety of zilurgisertib in patients ages 6 to <12 years of age (Cohort 2) and in patients ages 2 to <12 years of age (Cohort 3).

The primary endpoint of the study is the proportion of Cohort 1 patients with new heterotopic ossification (HO) lesions at Week 24 as assessed by whole-body CT scan data. Key secondary endpoints include the number and total volume of new HO lesions, changes in total HO lesion volume and flare activity through Week 24.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX).

Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), zilurgisertib, an ALK2 inhibitor under regulatory review with the FDA for fibrodysplasia ossificans progressiva (FOP), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).

Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at www.mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and X.

About Incyte®

Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation & Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.

Mirum Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the Company’s planned participation at a scientific congress, Mirum’s continued advancement of zilurgisertib with Incyte, the likelihood of a FDA approval pathway for zilurgisertib and the potential benefit of zilurgisertib in real world settings versus scientific presentations of data. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “expected,” “will,” “could,” “would,” “guidance,” “potential,” “continue” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Mirum’s business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Mirum’s Annual Report for the year ended December 31, 2025, filed with the Securities and Exchange Commission on February 25, 2026, and subsequent filings with the Securities and Exchange Commission, which are available at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Incyte Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the presentation of data from the PROGRESS study; the potential for zilurgisertib to become a treatment option for people living with FOP; expectations regarding ongoing and future clinical trials for zilurgisertib, including the timing of such trials; and Incyte’s aspirations and goals as set forth under the heading “About Incyte.”

Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including the sufficiency of clinical trial data to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; the efficacy or safety of Incyte’s and its partners’ products; the ability of Incyte and its partners to achieve commercial success for their marketed products and product candidates, if approved; Incyte’s and its partners’ ability to obtain and maintain protection of intellectual property for their products and technology; Incyte’s reliance on third parties and partners; the acceptance of Incyte’s and its partners’ products in the marketplace; market competition, sales, marketing, manufacturing and distribution requirements; greater than expected expenses, including expenses relating to litigation or strategic activities; and those risks and uncertainties discussed in greater detail in Incyte’s reports filed with the U.S. Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2025, and its quarterly report on Form 10-Q for the quarter ended March 31, 2026. Incyte disclaims any intent or obligation to update these forward-looking statements.

Mirum and the Mirum logo are trademarks of Mirum Pharmaceuticals, Inc.

More News From Mirum Pharmaceuticals, Inc. and Incyte

Discover why Toast (TOST +0.53%) is building a powerful restaurant operating system that could thrive beyond today's macro pressures. Watch the video below to see what long-term investors may want to know before making a move.

*This video was published on Jun. 12, 2026.

Danny Vena, CPA has positions in Toast. Karl Thiel has no position in any of the stocks mentioned. Rick Munarriz has positions in Toast. The Motley Fool has positions in and recommends Toast. The Motley Fool has a disclosure policy.

New York, New York--(Newsfile Corp. - June 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AeroVironment, Inc. (NASDAQ: AVAV) between June 25, 2025 and March 10, 2026, inclusive (the "Class Period"), of the important July 27, 2026 lead plaintiff deadline.

SO WHAT: If you purchased AeroVironment securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the AeroVironment class action, go to https://rosenlegal.com/cases/aerovironment-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) AeroVironment understated the likelihood that it would imminently face competition from other vendors for the work it performed in connection with the U.S. Space Force's Satellite Communication Augmentation Resources ("SCAR") program and the U.S. Space Force's ongoing efforts to modernize the Satellite Control Network ("SCN"); (2) accordingly, defendants overstated AeroVironment's business and financial prospects; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the AeroVironment class action, go to https://rosenlegal.com/cases/aerovironment-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301436

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - June 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Calix, Inc. (NYSE: CALX) between January 28, 2026 and April 21, 2026, inclusive (the "Class Period"), of the important July 27, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Calix securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Calix class action, go to https://rosenlegal.com/cases/calix-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Calix's first quarter margins had significantly benefited from advanced purchasing of memory components; (2) Calix's advanced supply of memory components was dwindling; (3) as a result, Calix was experiencing negative margin pressure as it was forced to purchase memory components at rising market prices; and (4) as a result of the foregoing, defendants' positive statements about Calix's margins, business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Calix class action, go to https://rosenlegal.com/cases/calix-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301440

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - June 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Badger Meter, Inc. (NYSE: BMI) between April 18, 2024 and April 16, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 3, 2026.

SO WHAT: If you purchased Badger Meter common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Badger Meter class action, go to https://rosenlegal.com/cases/badger-meter-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 3, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements concerning the drivers of Badger Meter's "record" financial results, demand for Badger Meter's products, and its prospects for continued growth. During the Class Period, defendants told investors that Badger Meter's strong financial results reflected "ongoing favorable industry trends," "secular growth drivers," and "solid operating execution." They likewise touted "strong" demand and said they were seeing "robust order pacing and a strong bid pipeline that positions us well for continued sales and earnings growth," and that Badger Meter possessed a "long runway" for growth.

According to the lawsuit, these statements were materially false and misleading. In truth, Badger Meter's financial results during the Class Period were at least partially attributable to Badger Meter's practice of pulling-forward customer orders to recognize revenue early, which concealed weakening demand and deteriorating near-term order trends. This practice also depleted revenue otherwise available for future periods, ultimately causing the disappointing financial results Badger Meter later reported. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Badger Meter class action, go to https://rosenlegal.com/cases/badger-meter-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301438

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Board of Directors member Stephen F. Reitman disclosed the sale of 17,981 shares of Capri Holdings Limited (CPRI +2.30%) in an open-market transaction on June 8, 2026, for total proceeds of approximately ~$349K, according to an SEC Form 4 filing.

Transaction summaryMetricValueShares sold (direct)17,981Transaction value~$349,000Post-transaction shares (direct)0Transaction value based on SEC Form 4 weighted average reported price ($19.42); post-transaction value is $0.00 since no shares were held after June 8, 2026.

Key questionsWhat does this sale indicate about Stephen Reitman's ownership position in Capri Holdings Limited?
This transaction reduced Reitman's direct and total ordinary share holdings to zero, marking a complete disposition of his equity position as of June 8, 2026.Was there any participation from indirect entities or derivative securities in this transaction?
No; the transaction involved only directly-held shares, with no reported activity from trusts, family entities, or stock options. Post-sale, Reitman held no direct or indirect interests.How does this sale compare to Reitman's historical trading activity?
This is the only open-market sale Reitman has made in the past three years, following a cadence of only administrative filings since August 2023.How did market conditions compare to the transaction price?
The shares were sold at a weighted average price around $19.42 per share, which was approximately 9.8% below the price of $21.33 as of June 12, 2026, and occurred after a one-year total return of 19.56% for the stock.Company overviewMetricValueEmployees10,200Revenue (TTM)$3.47 billionNet income (TTM)$137.00 million1-year price change19.56%Note: 1-year price change calculated using June 8th, 2026 as the reference date.

Company snapshotCapri Holdings offers luxury apparel, footwear, handbags, accessories, eyewear, watches, jewelry, fragrances, and home furnishings under the Jimmy Choo and Michael Kors brands.It generates revenue through a combination of direct-to-consumer retail, wholesale distribution, e-commerce, and global licensing agreements.The company targets affluent consumers and fashion-conscious clientele across North America, Europe, Asia, and other international markets.Capri Holdings Limited is a global luxury fashion group with a diversified brand portfolio and a broad international footprint.

The company leverages multi-channel distribution and licensing to maximize brand reach and capture value across multiple consumer segments. Its strategic focus on iconic brands and diversified revenue streams supports its competitive position in the global luxury goods sector.

What this transaction means for investorsThe June 8 sale of Capri Holdings stock by Board of Directors member Stephen Reitman is noteworthy, since it marks a complete liquidation of his holdings in the company. Even so, investors seemed unfazed as Capri shares rose after the transaction.

The Board member’s exit came at an interesting time for Capri. The company has struggled to generate sales, and in 2025, sold its flagging Versace brand. Revenue in Capri’s 2026 fiscal year ended March 28 was $3.5 billion, a decline from the prior year’s $3.6 billion.

On the bright side, the sale of Versace helped Capri achieve net income of $138 million. This is a significant turnaround from the $1.2 billion net loss suffered in its 2025 fiscal year.

Capri forecasted $3.5 billion in sales for its 2027 fiscal year, which signals an end to declining revenue if it can achieve this goal. However, Reitman’s exit from the stock does not bolster my confidence in the company’s ability to rebound from its current struggles.

Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

New York, New York--(Newsfile Corp. - June 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Lucid Group, Inc. (NASDAQ: LCID) between February 25, 2026 and April 13, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 28, 2026.

SO WHAT: If you purchased Lucid securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Lucid class action, go to https://www.rosenlegal.com/cases/lucid-group-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 28, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) a supplier quality issue had significantly disrupted deliveries of the Lucid Gravity; (2) the foregoing was likely to, and did, have a material negative impact on Lucid's business and financial results; (3) accordingly, the defendants had overstated the purported enhancements to Lucid's manufacturing and delivery capabilities and overall operations; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Lucid class action, go to https://www.rosenlegal.com/cases/lucid-group-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301401

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - June 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Graphic Packaging Holding Company (NYSE: GPK) between February 4, 2025 and February 2, 2026, inclusive (the "Class Period"), of the important July 6, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Graphic Packaging securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Graphic Packaging class action, go to https://rosenlegal.com/submit-form/?case_id=64523 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 6, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Graphic Packaging was experiencing, inter alia, significant inventory management issues, as well as significantly reduced demand and volumes and increased costs; (2) defendants downplayed the true scope and severity of the foregoing issues, which were likely to, and did, have a material negative impact on Graphic Packaging's business and financial results; (3) defendants likewise overstated the strength and sustainability of Graphic Packaging's business model and operations, as well as its ability to weather ongoing macroeconomic headwinds; (4) accordingly, Graphic Packaging's previously issued full year 2025 financial guidance was unreliable and/or unrealistic; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Graphic Packaging class action, go to https://rosenlegal.com/submit-form/?case_id=64523 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301426

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us